News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
Settle® immunotherapy for equine endometritis is now available in Canada. It's also sold in the USA, Australia, New Zealand and UAE. Settle is compatible with conventional treatments and is safe with natural breeding or AI.
NovaVive's immunotherapy for equine endometritis, Settle®, has received approval for sale in Canada from the Canadian Food Inspection Agency (CFIA). The product is expected to launch in the first quarter of this year.
An abstract has been presented at the 2023 AETA & CETA/ACTE Joint Convention in Orlando, FL summarizing a study showing a positive effect of MCWF (Amplimune) on pregnancy per embryo transfer for dairy cows with one lactation.
Data from a U.S. study using NovaVive's immunotherapy for equine endometritis, Settle®, to treat endometrial cups was presented today at the International Symposium on Equine Reproduction (ISER) in Foz do Iguaçu, Brazil.
Effective in June, 2023, all over-the-counter bovine antibiotics in the U.S. will be switched to prescription-only status. Amplimune immunotherapy offers an alternative to antibiotics that does not require a prescription.
NovaVive offers a USDA-approved immunotherapeutic, Equimune®, which has been recommended as a preventative treatment in horses exposed to Equine Herpes Virus (EHV-1). EHV-1 outbreaks are occurring with increasing frequency.